RATIONALE: Although observational studies suggest that clofazimine-containing regimens are highly active against drug-resistant tuberculosis, the contribution of clofazimine for the treatment of this disease has never been systematically evaluated. OBJECTIVES: Our goal was to directly compare the activity of a standard second-line drug regimen with or without the addition of clofazimine in a mouse model of multidrug-resistant tuberculosis. Our comparative outcomes included time to culture conversion in the mouse lungs and the percentage of relapses after treatment cessation. METHODS: Mice were aerosol-infected with an isoniazid-resistant (as a surrogate of multidrug-resistant) strain of Mycobacterium tuberculosis. Treatment, which was administered for 5 to 9 months, was initiated 2 weeks after infection and comprised the following second-line regimen: daily (5 d/wk) moxifloxacin, ethambutol, and pyrazinamide, supplemented with amikacin during the first 2 months. One-half of the mice also received daily clofazimine. The decline in lung bacterial load was assessed monthly using charcoal-containing agar to reduce clofazimine carryover. Relapse was assessed 6 months after treatment cessation. MEASUREMENTS AND MAIN RESULTS: After 2 months, the bacillary load in lungs was reduced from 9.74 log10 at baseline to 3.61 and 4.68 in mice treated with or without clofazimine, respectively (P < 0.001). Mice treated with clofazimine were culture-negative after 5 months, whereas all mice treated without clofazimine remained heavily culture-positive for the entire 9 months of the study. The relapse rate was 7% among mice treated with clofazimine for 8 to 9 months. CONCLUSIONS: The clofazimine contribution was substantial in these experimental conditions.
RATIONALE: Although observational studies suggest that clofazimine-containing regimens are highly active against drug-resistant tuberculosis, the contribution of clofazimine for the treatment of this disease has never been systematically evaluated. OBJECTIVES: Our goal was to directly compare the activity of a standard second-line drug regimen with or without the addition of clofazimine in a mouse model of multidrug-resistant tuberculosis. Our comparative outcomes included time to culture conversion in the mouse lungs and the percentage of relapses after treatment cessation. METHODS:Mice were aerosol-infected with an isoniazid-resistant (as a surrogate of multidrug-resistant) strain of Mycobacterium tuberculosis. Treatment, which was administered for 5 to 9 months, was initiated 2 weeks after infection and comprised the following second-line regimen: daily (5 d/wk) moxifloxacin, ethambutol, and pyrazinamide, supplemented with amikacin during the first 2 months. One-half of the mice also received daily clofazimine. The decline in lung bacterial load was assessed monthly using charcoal-containing agar to reduce clofazimine carryover. Relapse was assessed 6 months after treatment cessation. MEASUREMENTS AND MAIN RESULTS: After 2 months, the bacillary load in lungs was reduced from 9.74 log10 at baseline to 3.61 and 4.68 in mice treated with or without clofazimine, respectively (P < 0.001). Mice treated with clofazimine were culture-negative after 5 months, whereas all mice treated without clofazimine remained heavily culture-positive for the entire 9 months of the study. The relapse rate was 7% among mice treated with clofazimine for 8 to 9 months. CONCLUSIONS: The clofazimine contribution was substantial in these experimental conditions.
Authors: Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder Journal: Am J Respir Crit Care Med Date: 2010-05-04 Impact factor: 21.405
Authors: Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger Journal: J Infect Dis Date: 2012-07-17 Impact factor: 5.226
Authors: R E Chaisson; P Keiser; M Pierce; W J Fessel; J Ruskin; C Lahart; C A Benson; K Meek; N Siepman; J C Craft Journal: AIDS Date: 1997-03 Impact factor: 4.177
Authors: M C Cholo; H I Boshoff; H C Steel; R Cockeran; N M Matlola; K J Downing; V Mizrahi; R Anderson Journal: J Antimicrob Chemother Date: 2005-11-12 Impact factor: 5.790
Authors: Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger Journal: PLoS Med Date: 2007-12 Impact factor: 11.069
Authors: Vikram Saini; Nicole C Ammerman; Yong Seok Chang; Rokeya Tasneen; Richard E Chaisson; Sanjay Jain; Eric Nuermberger; Jacques H Grosset Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Bas C Mourik; Gerjo J de Knegt; Annelies Verbon; Johan W Mouton; Hannelore I Bax; Jurriaan E M de Steenwinkel Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191
Authors: N Padayatchi; M Gopal; R Naidoo; L Werner; K Naidoo; I Master; M R O'Donnell Journal: J Antimicrob Chemother Date: 2014-06-30 Impact factor: 5.790
Authors: Sandeep Tyagi; Nicole C Ammerman; Si-Yang Li; John Adamson; Paul J Converse; Rosemary V Swanson; Deepak V Almeida; Jacques H Grosset Journal: Proc Natl Acad Sci U S A Date: 2015-01-05 Impact factor: 11.205
Authors: Rosemary V Swanson; Nicole C Ammerman; Bongani Ngcobo; John Adamson; Chivonne Moodley; Afton Dorasamy; Sashen Moodley; Zinhle Mgaga; Linda A Bester; Sanil D Singh; Deepak V Almeida; Jacques H Grosset Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191